AAVANTIBIO
Live / Applied — Fourth extension granted (statement of use) (as of 11 Jul 2025)
What this means for you
Not registered yet, but its 05 Jan 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97203384
- Mark type
- Stylized text
- Filed
- 05 Jan 2022
- Published for opposition
- 16 May 2023
- Attorney of record
- Jonathan M. Gelchinsky
Goods and services
- Class 005 — Pharmaceuticals: Biological treatments, namely, biological preparations for use in the clinical, medicinal, and therapeutic treatment of Friedreich's Ataxia, genetic disorders, genetic diseases, and rare diseases; biopharmaceutical reagents for medical use, for use in gene therapy for the treatment of Friedreich's Ataxia, genetic disorders, genetic diseases, and rare diseases; biopharmaceutical preparations for human use for the treatment of Friedreich's Ataxia, genetic disorders, genetic diseases, and rare diseases
Owner
- Aavantibio, Inc., Cambridge, MA, US
- Aavantibio, Inc., Cambridge, MA, US
Prosecution history
- 16 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jul 2025 — SOU EXTENSION 4 GRANTED
- 11 Jul 2025 — SOU EXTENSION 4 FILED
- 11 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jan 2025 — SOU EXTENSION 3 GRANTED
- 10 Jan 2025 — SOU EXTENSION 3 FILED
- 10 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jul 2024 — SOU EXTENSION 2 GRANTED
- 11 Jul 2024 — SOU EXTENSION 2 FILED
- 11 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 06 Jan 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Jan 2024 — SOU EXTENSION 1 GRANTED